This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heartvalves (SEV). Forty-seven received SEVs using COL, and 50 with CON techniques.
The program directors have chosen an ambitious theme of "The Taming of the AorticValves," inspired by Shakespeare's classic The Taming of the Shrew. There will also be an in-depth discussion on the lifelong management of aorticvalve surgery patients.
The conference theme is “Goldilocks: Toward the Optimal Mitral Valve,” and the organizers aim to bring together distinguished experts from around the world to share their knowledge and engage in academic discussions on the latest trends in treatments related to aorticvalve disease. Details coming soon!
A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aorticvalve replacement (TAVR) using Evolut TAVR compared to surgical aorticvalve replacement (SAVR) for low-risk patients. Francis Hospital , and faculty member at Columbia University. mmHg TAVR; 11.8
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content